Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Catherine Thiéblemont; Tycel Phillips; Hervé Ghesquières; Chan Y. Cheah; Michael Roost Clausen; David Cunningham; Young Rok; Tatyana Feldman; Robin Gasiorowski; Wojciech Jurczak; Tae Min Kim; David Lewis; Marjolein van der Poel; Michelle Poon; Mariana Cota Stirner; Nurgul Kilavuz; Christopher Chiu; Menghui Chen; Mariana Sacchi; Brian Elliott; Tahamtan Ahmadi; Martin Hutchings; Pieternella J. Lugtenburg

doi:10.1200/jco.22.01725

Abstract

This is the authors' abstract. We don't add key points for this paper.

Subcutaneous epcoritamab resulted in deep and durable responses and manageable safety in highly refractory patients with large B-cell lymphoma, including those with prior CAR T-cell exposure.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Thiéblemont et al. (2022) studied this question.

synapsesocial.com/papers/69df0849d5404a0bea591826 https://doi.org/10.1200/jco.22.01725

View Full Paper

Ask AI

Bookmark

Abstract

This is the authors' abstract. We don't add key points for this paper.

Subcutaneous epcoritamab resulted in deep and durable responses and manageable safety in highly refractory patients with large B-cell lymphoma, including those with prior CAR T-cell exposure.

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Abstract

Ask about this paper

Discussion

Cite This Study

Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading